ReviewFrontiers in microbiology2026
The roles of gut microbiota and their metabolites in uric acid-related metabolic diseases: mechanisms and therapeutic targets.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota and their metabolites play a central regulatory role in uric-acid-related metabolic diseases, serving as a crucial interface linking purine metabolism with host inflammatory responses. This review synthesizes current evidence on microbial community alterations, metabolic functional shifts, and receptor-mediated signaling mechanisms in hyperuricemia, gout, and uric acid nephropathy. Studies demonstrate that gut microbes can directly degrade purine substrates, modulate uric acid transporters and metabolic enzyme activity, and regulate host pathways through metabolites such as short-chain fatty acids, bile acids, and indole derivatives acting on receptors including GPR41 and GPR43. These interactions collectively shape the dynamic balance between uric acid production and excretion. Probiotic and prebiotic interventions, such as
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.